FDAnews
www.fdanews.com/articles/96674-axcan-pharma-submits-complete-new-drug-application-for-ultrase

Axcan Pharma Submits Complete New Drug Application for Ultrase

August 2, 2007

Axcan Pharma Inc. (“Axcan” or the “Company”) announced that it has submitted the complete New Drug Application (“NDA”) for Ultrase in the treatment of Exocrine Pancreatic Insufficiency (“EPI”), with the U.S. Food and Drug Administration (“FDA”).
Marketwire